Technical Analysis for ACRX - AcelRx Pharmaceuticals, Inc.
|Grade||Last Price||% Change||Price Change|
ACRX closed unchanged on Thursday, April 27, 2017, on 44 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: May 1
Trend Table & Recent Alerts
|See historical ACRX trend table...|
|Date||Alert Name||Type||% Chg|
|Apr 25||Reversal New Lows Setup||Bearish Swing Setup||1.96%|
|Apr 24||Doji - Bullish?||Reversal||0.00%|
|Apr 21||Stochastic Reached Oversold||Other||1.96%|
|Apr 21||New Downtrend||Bearish||1.96%|
|Apr 20||Calm After Storm||Range Contraction||-3.70%|
|Apr 19||Narrow Range Bar||Range Contraction||-1.89%|
|Apr 19||Lower Bollinger Band Walk||Other||-1.89%|
|Apr 19||180 Bearish Setup||Bearish Swing Setup||-1.89%|
|Apr 19||Calm After Storm||Range Contraction||-1.89%|
|Apr 18||Lower Bollinger Band Walk||Other||-3.70%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
AcelRx Pharmaceuticals, Inc., a development stage specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute and breakthrough pain. The companys principal product candidate is ARX-01, a Sufentanil NanoTab PCA system, which is in Phase III clinical trials for acute post-operative pain in patients in the hospital setting. Its product candidates also comprise ARX-02, a Sufentanil NanoTab BTP management system that has completed a Phase II clinical trial for the treatment of cancer patients who suffer from breakthrough pain; and ARX-03, a Sufentanil/Triazolam NanoTab, which has completed a Phase II clinical trial to provide mild sedation, anxiety reduction, and pain relief for patients undergoing painful procedures in a physicians office. In addition, the companys product candidate under development includes ARX-04, a Sufentanil Single-Dose NanoTab for the treatment of patients with moderate-to-severe acute pain either on the battlefield or in civilian settings of trauma or injury. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.
Is ACRX a Buy, Sell or Hold?
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more ACRX news...
|52 Week High||4.08|
|52 Week Low||2.4|
|200-Day Moving Average||3.0889|
|50-Day Moving Average||2.974|
|20-Day Moving Average||2.7738|
|10-Day Moving Average||2.645|
|Average True Range||0.1313|
|Chandelier Exit (Long, 3 ATRs)||2.8061|
|Chandelier Exit (Short, 3 ATRs)||2.8939|
|Upper Bollinger Band||3.1369|
|Lower Bollinger Band||2.4107|
|Percent B (%b)||0.26|